Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Reversible mechanisms of enzyme inhibition and resulting clinical significance.

Ring B, Wrighton SA, Mohutsky M.

Methods Mol Biol. 2014;1113:37-56. doi: 10.1007/978-1-62703-758-7_4. Review.

PMID:
24523108
2.

Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.

Baker JA, Wickremsinhe ER, Li CH, Oluyedun OA, Dantzig AH, Hall SD, Qian YW, Ring BJ, Wrighton SA, Guo Y.

Drug Metab Dispos. 2013 Mar;41(3):541-5. doi: 10.1124/dmd.112.048769. Epub 2012 Dec 10.

PMID:
23230131
3.

Arsenic decreases RXRα-dependent transcription of CYP3A and suppresses immune regulators in hepatocytes.

Noreault-Conti TL, Fellows A, Jacobs JM, Trask HW, Strom SC, Evans RM, Wrighton SA, Sinclair PR, Sinclair JF, Nichols RC.

Int Immunopharmacol. 2012 Apr;12(4):651-6. doi: 10.1016/j.intimp.2012.01.008. Epub 2012 Feb 4.

4.

Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.

Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, Hall SD.

Drug Metab Dispos. 2012 Apr;40(4):706-16. doi: 10.1124/dmd.111.043158. Epub 2012 Jan 6.

PMID:
22228749
5.

Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human.

Williams ET, Bacon JA, Bender DM, Lowinger JJ, Guo WK, Ehsani ME, Wang X, Wang H, Qian YW, Ruterbories KJ, Wrighton SA, Perkins EJ.

Drug Metab Dispos. 2011 Dec;39(12):2305-13. doi: 10.1124/dmd.111.041335. Epub 2011 Sep 14.

PMID:
21918037
6.

Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.

Yang J, He MM, Niu W, Wrighton SA, Li L, Liu Y, Li C.

Br J Clin Pharmacol. 2012 Feb;73(2):268-84. doi: 10.1111/j.1365-2125.2011.04076.x.

7.

Potentially increasing the metabolic stability of drug candidates via computational site of metabolism prediction by CYP2C9: The utility of incorporating protein flexibility via an ensemble of structures.

Danielson ML, Desai PV, Mohutsky MA, Wrighton SA, Lill MA.

Eur J Med Chem. 2011 Sep;46(9):3953-63. doi: 10.1016/j.ejmech.2011.05.067. Epub 2011 Jun 23.

8.

Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma.

Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, Hall SD.

Drug Metab Dispos. 2011 Apr;39(4):591-602. doi: 10.1124/dmd.110.036400. Epub 2011 Jan 6.

PMID:
21212240
9.

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.

Gueorguieva I, Jackson K, Wrighton SA, Sinha VP, Chien JY.

Br J Clin Pharmacol. 2010 Oct;70(4):523-36. doi: 10.1111/j.1365-2125.2010.03731.x.

10.

Genomic analysis of the carboxylesterases: identification and classification of novel forms.

Williams ET, Wang H, Wrighton SA, Qian YW, Perkins EJ.

Mol Phylogenet Evol. 2010 Oct;57(1):23-34. doi: 10.1016/j.ympev.2010.05.018. Epub 2010 May 25.

PMID:
20510380
11.

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.

Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W.

Pharmacogenomics J. 2011 Aug;11(4):274-86. doi: 10.1038/tpj.2010.28. Epub 2010 Apr 13.

12.

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.

Farid NA, Kurihara A, Wrighton SA.

J Clin Pharmacol. 2010 Feb;50(2):126-42. doi: 10.1177/0091270009343005. Epub 2009 Nov 30. Review. Erratum in: J Clin Pharmacol. 2010 Apr;50(4):483.

PMID:
19948947
13.

Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes.

Dennison JB, Mohutsky MA, Barbuch RJ, Wrighton SA, Hall SD.

J Pharmacol Exp Ther. 2008 Oct;327(1):248-57. doi: 10.1124/jpet.108.139998. Epub 2008 Jul 23.

PMID:
18650247
14.

PhRMA white paper on ADME pharmacogenomics.

Williams JA, Andersson T, Andersson TB, Blanchard R, Behm MO, Cohen N, Edeki T, Franc M, Hillgren KM, Johnson KJ, Katz DA, Milton MN, Murray BP, Polli JW, Ricci D, Shipley LA, Vangala S, Wrighton SA.

J Clin Pharmacol. 2008 Jul;48(7):849-89. doi: 10.1177/0091270008319329. Epub 2008 Jun 4. Review.

PMID:
18524998
15.

The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.

Williams ET, Jones KO, Ponsler GD, Lowery SM, Perkins EJ, Wrighton SA, Ruterbories KJ, Kazui M, Farid NA.

Drug Metab Dispos. 2008 Jul;36(7):1227-32. doi: 10.1124/dmd.107.020248. Epub 2008 Mar 27.

PMID:
18372401
16.

Effect of buffer components and carrier solvents on in vitro activity of recombinant human carboxylesterases.

Williams ET, Ehsani ME, Wang X, Wang H, Qian YW, Wrighton SA, Perkins EJ.

J Pharmacol Toxicol Methods. 2008 Mar-Apr;57(2):138-44. doi: 10.1016/j.vascn.2007.11.003. Epub 2007 Dec 5.

PMID:
18248745
17.

Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.

Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B, Li C.

Drug Metab Dispos. 2007 Aug;35(8):1292-300. Epub 2007 Apr 30.

PMID:
17470523
18.

Role of CYP3A and CYP2E1 in alcohol-mediated increases in acetaminophen hepatotoxicity: comparison of wild-type and Cyp2e1(-/-) mice.

Wolf KK, Wood SG, Allard JL, Hunt JA, Gorman N, Walton-Strong BW, Szakacs JG, Duan SX, Hao Q, Court MH, von Moltke LL, Greenblatt DJ, Kostrubsky V, Jeffery EH, Wrighton SA, Gonzalez FJ, Sinclair PR, Sinclair JF.

Drug Metab Dispos. 2007 Jul;35(7):1223-31. Epub 2007 Mar 28.

PMID:
17392391
19.

Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity.

Kolwankar D, Vuppalanchi R, Ethell B, Jones DR, Wrighton SA, Hall SD, Chalasani N.

Clin Gastroenterol Hepatol. 2007 Mar;5(3):388-93.

PMID:
17368239
20.

Effect of proteasome inhibition on toxicity and CYP3A23 induction in cultured rat hepatocytes: comparison with arsenite.

Noreault-Conti TL, Jacobs JM, Trask HW, Wrighton SA, Sinclair JF, Nichols RC.

Toxicol Appl Pharmacol. 2006 Dec 15;217(3):245-51. Epub 2006 Sep 22.

PMID:
17083955
21.

Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis.

Crumb WJ Jr, Ekins S, Sarazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM Jr.

Pharm Res. 2006 Jun;23(6):1133-43. Epub 2006 May 25.

PMID:
16715368
22.

Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.

Chien JY, Lucksiri A, Ernest CS 2nd, Gorski JC, Wrighton SA, Hall SD.

Drug Metab Dispos. 2006 Jul;34(7):1208-19. Epub 2006 Apr 12.

PMID:
16611859
23.

Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.

Mohutsky MA, Chien JY, Ring BJ, Wrighton SA.

Pharm Res. 2006 Apr;23(4):654-62. Epub 2006 Mar 24.

PMID:
16550474
24.

Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity.

Yohe HC, O'Hara KA, Hunt JA, Kitzmiller TJ, Wood SG, Bement JL, Bement WJ, Szakacs JG, Wrighton SA, Jacobs JM, Kostrubsky V, Sinclair PR, Sinclair JF.

Am J Physiol Gastrointest Liver Physiol. 2006 Jun;290(6):G1269-79. Epub 2006 Jan 26.

25.

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ.

Drug Metab Dispos. 2006 Apr;34(4):600-7. Epub 2006 Jan 13.

PMID:
16415119
26.

Role of the nuclear receptor pregnane X receptor in acetaminophen hepatotoxicity.

Wolf KK, Wood SG, Hunt JA, Walton-Strong BW, Yasuda K, Lan L, Duan SX, Hao Q, Wrighton SA, Jeffery EH, Evans RM, Szakacs JG, von Moltke LL, Greenblatt DJ, Court MH, Schuetz EG, Sinclair PR, Sinclair JF.

Drug Metab Dispos. 2005 Dec;33(12):1827-36. Epub 2005 Sep 1.

PMID:
16141365
27.

Comparison of human and monkey peptide transporters: PEPT1 and PEPT2.

Zhang EY, Emerick RM, Pak YA, Wrighton SA, Hillgren KM.

Mol Pharm. 2004 May-Jun;1(3):201-10.

PMID:
15981923
28.

Mechanism of arsenite-mediated decreases in CYP3A23 in rat hepatocytes.

Noreault TL, Jacobs JM, Nichols RC, Trask HW, Wrighton SA, Sinclair PR, Sinclair JF.

Biochem Biophys Res Commun. 2005 Aug 12;333(4):1211-7.

PMID:
15979568
29.

Arsenite decreases CYP3A23 induction in cultured rat hepatocytes by transcriptional and translational mechanisms.

Noreault TL, Jacobs JM, Nichols RC, Trask HW, Wrighton SA, Sinclair PR, Evans RM, Sinclair JF.

Toxicol Appl Pharmacol. 2005 Dec 1;209(2):174-82.

PMID:
15907335
30.

Arsenite decreases CYP3A4 and RXRalpha in primary human hepatocytes.

Noreault TL, Kostrubsky VE, Wood SG, Nichols RC, Strom SC, Trask HW, Wrighton SA, Evans RM, Jacobs JM, Sinclair PR, Sinclair JF.

Drug Metab Dispos. 2005 Jul;33(7):993-1003. Epub 2005 Apr 15.

PMID:
15833926
31.

The use of a substrate cassette strategy to improve the capacity and throughput of cytochrome P450 induction studies in human hepatocytes.

Mohutsky MA, Petullo DM, Wrighton SA.

Drug Metab Dispos. 2005 Jul;33(7):920-3. Epub 2005 Mar 31.

PMID:
15802386
32.

Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.

Ring BJ, Patterson BE, Mitchell MI, Vandenbranden M, Gillespie J, Bedding AW, Jewell H, Payne CD, Forgue ST, Eckstein J, Wrighton SA, Phillips DL.

Clin Pharmacol Ther. 2005 Jan;77(1):63-75.

PMID:
15637532
33.

Estrogen regulation of the cytochrome P450 3A subfamily in humans.

Williams ET, Leyk M, Wrighton SA, Davies PJ, Loose DS, Shipley GL, Strobel HW.

J Pharmacol Exp Ther. 2004 Nov;311(2):728-35. Epub 2004 Jul 28.

PMID:
15282264
34.

Role of mouse CYP2E1 in the O-hydroxylation of p-nitrophenol: comparison of activities in hepatic microsomes from Cyp2e1(-/-) and wild-type mice.

Wolf KK, Wood SG, Bement JL, Sinclair PR, Wrighton SA, Jeffery E, Gonzalez FJ, Sinclair JF.

Drug Metab Dispos. 2004 Jul;32(7):681-4.

PMID:
15205381
35.

PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5.

Schuetz EG, Relling MV, Kishi S, Yang W, Das S, Chen P, Cook EH, Rosner GL, Pui CH, Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, Camitta BM, Raimondi SC, Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Lim R, Lim HL, Ong AB, Lee HS, Kuehl P, Zhang J, Lin Y, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS.

Pharmacol Rev. 2004 Jun;56(2):159. No abstract available.

PMID:
15169924
36.

Genetic polymorphisms in human proton-dependent dipeptide transporter PEPT1: implications for the functional role of Pro586.

Zhang EY, Fu DJ, Pak YA, Stewart T, Mukhopadhyay N, Wrighton SA, Hillgren KM.

J Pharmacol Exp Ther. 2004 Aug;310(2):437-45. Epub 2004 Apr 9.

PMID:
15075386
37.

An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes.

Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA.

Drug Metab Dispos. 2004 Jan;32(1):140-8.

PMID:
14709631
38.

Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.

Sauer JM, Long AJ, Ring B, Gillespie JS, Sanburn NP, DeSante KA, Petullo D, VandenBranden MR, Jensen CB, Wrighton SA, Smith BP, Read HA, Witcher JW.

J Pharmacol Exp Ther. 2004 Feb;308(2):410-8. Epub 2003 Nov 10.

PMID:
14610241
39.

Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression.

Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, Schuetz EG.

J Pharmacol Exp Ther. 2003 Dec;307(3):906-22. Epub 2003 Oct 9.

PMID:
14551287
40.

Physiological approaches to the prediction of drug-drug interactions in study populations.

Chien JY, Mohutsky MA, Wrighton SA.

Curr Drug Metab. 2003 Oct;4(5):347-56. Review.

PMID:
14529367
41.

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER).

Drug Metab Dispos. 2003 Jul;31(7):815-32.

PMID:
12814957
42.

The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases.

Soars MG, Ring BJ, Wrighton SA.

Drug Metab Dispos. 2003 Jun;31(6):762-7.

PMID:
12756209
43.

The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.

Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups.

J Clin Pharmacol. 2003 May;43(5):443-69. Review.

PMID:
12751267
44.

Biosynthesis of drug glucuronides for use as authentic standards.

Soars MG, Mattiuz EL, Jackson DA, Kulanthaivel P, Ehlhardt WJ, Wrighton SA.

J Pharmacol Toxicol Methods. 2002 May-Jun;47(3):161-8.

PMID:
12628307
45.

A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro.

Fayer JL, Petullo DM, Ring BJ, Wrighton SA, Ruterbories KJ.

J Pharmacol Toxicol Methods. 2001 Sep-Oct;46(2):117-23.

PMID:
12481849
46.

Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes.

Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, Wrighton SA.

Drug Metab Dispos. 2002 Nov;30(11):1266-73.

PMID:
12386134
47.

The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450.

Ring BJ, Gillespie JS, Binkley SN, Campanale KM, Wrighton SA.

Drug Metab Dispos. 2002 Sep;30(9):957-61.

PMID:
12167559
48.

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA.

Drug Metab Dispos. 2002 Aug;30(8):883-91.

PMID:
12124305
49.

Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates.

Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA.

Mol Pharmacol. 2002 May;61(5):974-81.

PMID:
11961114
50.

Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.

Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA.

Mol Pharmacol. 2002 May;61(5):964-73.

PMID:
11961113

Supplemental Content

Loading ...
Support Center